Physician profile
Thomas Hickey
NPI 1851515738
$2,648.61
in general payments reported to CMS, 2019-2025
24 companies · $354 in 2025
The $354 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $342 · 2021: $548 · 2022: $384 · 2023: $155 · 2024: $367 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $552.19 | 2019-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $260.61 | 2019-2023 | Doc Band |
| Corium, LLC | $250.16 | 2022-2025 | Azstarys |
| Pfizer INC. | $210.60 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $154.37 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Supernus Pharmaceuticals, INC. | $134.33 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $131.43 | 2019-2024 | |
| Adlon Therapeutics L.P. | $130.09 | 2019-2021 | |
| Kaleo, INC. | $105.63 | 2019-2022 | |
| Sanofi Pasteur INC. | $97.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $84.87 | 2019-2021 | |
| Genentech USA, INC. | $78.55 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $73.95 | 2021-2025 | Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $63.61 | 2019-2022 | |
| Welch Allyn | $53.45 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $46.57 | 2021-2024 | Kristalose |
| Neos Therapeutics, Lp | $42.28 | 2019 | |
| Collegium Pharmaceutical, INC. | $36.38 | 2025 | Jornay Pm |
| Shire North American Group INC | $30.61 | 2019 | |
| Seqirus USA INC | $29.48 | 2021 | |
| Sobi, INC | $23.98 | 2020 | |
| Alk-Abello, INC | $22.60 | 2024 | Ragwitek, Odactra, Grastek |
| Vertical Pharmaceuticals, LLC | $18.92 | 2024 | Relexxii |
| Novo Nordisk INC | $16.30 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.